438 related articles for article (PubMed ID: 37328635)
21. Bispecific Antibodies for the Treatment of Multiple Myeloma.
Goldsmith SR; Streeter S; Covut F
Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
[TBL] [Abstract][Full Text] [Related]
22. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
Firestone R; Lesokhin AM; Usmani SZ
Blood Cancer Discov; 2023 Nov; 4(6):433-436. PubMed ID: 37824758
[TBL] [Abstract][Full Text] [Related]
23. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
24. Bispecific Antibodies in the Treatment of Multiple Myeloma.
Zhou X; Xiao X; Kortuem KM; Einsele H
Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
[TBL] [Abstract][Full Text] [Related]
25. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
[TBL] [Abstract][Full Text] [Related]
26. Antibody therapies for multiple myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
[No Abstract] [Full Text] [Related]
27. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
28. Current use of bispecific antibodies to treat multiple myeloma.
Lee H; Neri P; Bahlis NJ
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
[TBL] [Abstract][Full Text] [Related]
29. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau P; Touzeau C
Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
[TBL] [Abstract][Full Text] [Related]
30. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
31. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
32. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
[TBL] [Abstract][Full Text] [Related]
33. Bispecific Antibodies in Multiple Myeloma: Present and Future.
Lancman G; Sastow DL; Cho HJ; Jagannath S; Madduri D; Parekh SS; Richard S; Richter J; Sanchez L; Chari A
Blood Cancer Discov; 2021 Sep; 2(5):423-433. PubMed ID: 34661161
[TBL] [Abstract][Full Text] [Related]
34. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy.
Casey M; Lee C; Kwok WY; Law SC; Corvino D; Gandhi MK; Harrison SJ; Nakamura K
Haematologica; 2024 Mar; 109(3):787-798. PubMed ID: 37767564
[TBL] [Abstract][Full Text] [Related]
36. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
37. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Mutlu YG; Yıgıt Kaya S; Maral S; Melek E; Baslar Z; Kaynar L; Sevindik OG
Front Immunol; 2023; 14():1276295. PubMed ID: 37901215
[TBL] [Abstract][Full Text] [Related]
38. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Chari A; Askari E; Caers J; Costa LJ; Hilder BW; Krishnan A; Mateos MV; Minnema MC; Oriol A; Pillarisetti K; van de Donk NWCJ; Rodríguez-Otero P
Future Oncol; 2023 Sep; 19(27):1823-1840. PubMed ID: 37492991
[TBL] [Abstract][Full Text] [Related]
39. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
O'Neill C; van de Donk NWCJ
EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
[TBL] [Abstract][Full Text] [Related]
40. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
